Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Open accessThe DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.
Abstract
Background: The glutamatergic modulator ketamine has created a blueprint for studying novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic psychedelics (SPs) may also have antidepressant efficacy. Both ketamine and SPs appear to produce rapid, sustained antidepressant effects after a transient psychoactive period. Methods: This review summarizes areas of overlap between SP and ketamine research and considers the possibility of a common, downstream mechanism of action. The therapeutic relevance of the psychoactive state, overlapping cellular and molecular effects, and overlapping electrophysiological and neuroimaging observations are all reviewed. Results: Taken together, the evidence suggests a potentially shared mechanism wherein both ketamine and SPs may engender rapid neuroplastic effects in a glutamatergic activity-dependent manner. It is postulated that, though distinct, both ketamine and SPs appear to produce acute alterations in cortical network activity that may initially produce psychoactive effects and later produce milder, sustained changes in network efficiency associated with therapeutic response. However, despite some commonalities between the psychoactive component of these pharmacologically distinct therapies—such as engagement of the downstream glutamatergic pathway—the connection between psychoactive impact and antidepressant efficacy remains unclear and requires more rigorous research. Conclusions: Rapid-acting antidepressants currently under investigation may share some downstream pharmacological effects, suggesting that their antidepressant effects may come about via related mechanisms. Given the prototypic nature of ketamine research and recent progress in this area, this platform could be used to investigate entirely new classes of antidepressants with rapid and robust actions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In recent years, accumulating evidence indicates that psychedelic compounds that bind 5-HT 2A Rs rapidly promote neural plasticity both structurally and functionally, suggesting that this is a potential mechanism underlying the therapeutic effects of psychedelics (Olson, 2018;Inserra et al., 2021a;Kadriu et al., 2021).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Kadriu et al., 2021
In the citing paper
“In recent years, accumulating evidence indicates that psychedelic compounds that bind 5-HT 2A Rs rapidly promote neural plasticity both structurally and functionally, suggesting that this is a potential mechanism underlying the therapeutic effects of psychedelics (Olson, 2018;Inserra et al., 2021a;Kadriu et al., 2021).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Kadriu et al., 2021
In the citing paper
“Ketamine and its enantiomers do not only antagonize the N-methyl-D-aspartate (NMDA) receptors, but also induce rapid brain-derived neurotrophic factor (BDNF) translation and release in brain areas, which is supposed to be responsible for neuroplastic effects [17].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [17]
In the citing paper
“To date, reviews have focused on establishing treatment efficacy [30], understanding the neurological mechanisms of change [71], or have been broad in their aims (e.g. including a variety of drug classes or disorders [72, 73];).”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [73]
In the citing paper
“Recent studies have shown that NMDA receptor antagonists like ketamine and 5-HT2A receptor agonists like serotonergic psychedelics (the most studied include lysergic acid diethylamide/LSD and psilocybin) induce rapid and sometimes robust antidepressant effects190-193.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [192]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Buzsáki, G. (2006) · doi:10.1093/acprof:oso/9780195301069.001.0001 · Cited by 4,873
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“This AMPA activity appears to be critical, as rodent studies found that AMPA antagonists abolished ketamine’s behavioral, antidepressant, and mTORstimulating effects (Moghaddam et al., 1997; Maeng et al., 2008; Li et al., 2010).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“ketamine injections resulted in an antidepressant response observed concurrently with increased brain-derived neutrotrophic factor (Bdnf) gene expression and translation in the hippocampus and across the cortex (Garcia et al., 2008; Autry et al., 2011; Silva Pereira et al., 2017).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Default Mode Network Activity and Connectivity in Psychopathology
Whitfield-Gabrieli, S., & Ford, J. M. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143049 · Cited by 1,465 · cited 1×
“Another area of particular interest is alterations in default mode network (DMN) functional connectivity, consistent with a growing body of literature reporting the relevance of DMN activity to the pathophysiology of depression (Whitfield-Gabrieli and Ford, 2012; Barrett and Griffiths, 2018; Li et al., 2018).”
BackgroundHomayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“2 mg/kg) vs a niacin placebo (n = 12) reported significant improvement in Beck Depression Inventory scores in individuals with advanced-stage cancer and anxiety disorders, but only after 6 months (Grob et al., 2011).”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 10×
“RSFC between the DMN and the insula (part of the salience network), which was reduced in MDD participants compared with HVs prior to treatment, normalized in MDD participants following ketamine and returned to baseline at the time point when most participants relapsed (Evans et al., 2018).”
BackgroundInfluentialMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationTowards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 1×
“In addition, a placebo-controlled pilot study found that LSD produced trend-level reductions in HADS scores 2 months post-administration in 12 participants experiencing end-of-life anxiety (Gasser et al., 2014).”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 2×
“In terms of immediate drug effects, both ketamine and SPs appear to trigger a “glutamate surge” (Razoux et al., 2007; Vollenweider and Kometer, 2010).”
BackgroundThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · cited 2×
“With regard to SPs, a recent study looked at changes in RSFC in 19 TRD participants 1 day after the second of 2 psilocybin administrations (8 days after the first) and found increased DMN connectivity post-treatment (Carhart-Harris and Goodwin, 2017); stronger RSFC between particular nodes predicted sustained response…”
BackgroundGaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
Global Connectivity of Prefrontal Cortex Predicts Cognitive Control and Intelligence
Cole, M. W., Yarkoni, T., Repovs, G., Anticevic, A., & Braver, T. S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0536-12.2012 · Cited by 613 · cited 1×
“Three studies exploring ketamine’s effects on connectivity measured via global brain connectivity (GBC)—a graph-based measure of intrinsic whole-brain network connectivity (Cole et al., 2012)—suggested it may be a biomarker of antidepressant response; individuals who responded to ketamine had higher delta GBCr values…”
BackgroundJohnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Vaidya, V. A., Marek, G. J., Aghajanian, G. K., & Duman, R. S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02785.1997 · Cited by 479
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2063-13.2013 · Cited by 475
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 1×
“, 2015) and 14 (Sanches et al., 2016) depressed participants given Ayahuasca, International Journal of Neuropsychopharmacology (2021) 24(1): 8–21”
BackgroundGarcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017) · Scientific Reports · doi:10.1038/srep46421 · Cited by 410
Is it time to reassess the BDNF hypothesis of depression?
Groves, J. O. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002075 · Cited by 404
Liu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Enhanced repertoire of brain dynamical states during the psychedelic experience
Tagliazucchi, E., Carhart‐Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014) · Human Brain Mapping · doi:10.1002/hbm.22562 · Cited by 397
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359
Self-citationKometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Gerhard, D. M., Pothula, S., Liu, R.-J., Wu, M., Li, X.-Y., Girgenti, M. J., Taylor, S. R., Duman, C. H., Delpire, E., Picciotto, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130808 · Cited by 345
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335 · cited 1×
“Our understanding of antidepressant pharmacotherapy dramatically changed with the discovery that subanesthetic doses of the glutamatergic modulator ketamine exert antidepressant effects in a matter of minutes and that these effects persist long after drug excretion (Hashimoto, 2019).”
BackgroundA brain network model for depression: From symptom understanding to disease intervention
Li, B., Friston, K., Mody, M., Wang, H., Lu, H., & Hu, D. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12998 · Cited by 334
Ketamine Treatment and Global Brain Connectivity in Major Depression
Abdallah, C. G., Averill, L. A., Collins, K. A., Geha, P., Schwartz, J., Averill, C., DeWilde, K. E., Wong, E., Anticevic, A., Tang, C. Y., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.186 · Cited by 300
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273
The hidden therapist: evidence for a central role of music in psychedelic therapy
Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4820-5 · Cited by 267
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267
Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258
Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics
Olson, D. E. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518800508 · Cited by 257 · cited 1×
“With regard to ketamine, the glutamate surge associated with its administration translates into increased AMPAR throughput, which likely triggers BDNF release and activates mTOR (Duman, 2018; Olson, 2018).”
BackgroundDuncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256
Self-citationClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
Abdallah, C. G., De Feyter, H. M., Averill, L. A., Jiang, L., Averill, C. L., Chowdhury, G. M. I., Purohit, P., de Graaf, R. A., Esterlis, I., Juchem, C., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0136-3 · Cited by 229
dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1511424 · Cited by 227
Puig, M. V. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.8.870 · Cited by 222
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213 · cited 1×
“However, the evidence is mixed for ketamine, with some studies supporting these findings (Laje et al., 2012; Duncan et al., 2013; Haile et al., 2014) and other studies finding no such evidence (Machado-Vieira et al.”
ResultSelf-citationMertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895520 · Cited by 208
Bonhomme, V., Vanhaudenhuyse, A., Demertzi, A., Bruno, M.-A., Jaquet, O., Bahri, M. A., Plenevaux, A., Boly, M., Boveroux, P., Soddu, A., et al. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001275 · Cited by 207
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205
Widman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
Cornwell, B. R., Salvadore, G., Furey, M., Marquardt, C. A., Brutsche, N. E., Grillon, C., & Zarate, C. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.029 · Cited by 200
Self-citationChowdhury, G. M. I., Zhang, J., Thomas, M., Banasr, M., Ma, X., Pittman, B., Bristow, L., Schaeffer, E., Duman, R. S., Rothman, D. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.34 · Cited by 197
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Bagot, R. C., Cates, H. M., Purushothaman, I., Vialou, V., Heller, E. A., Yieh, L., LaBonté, B., Peña, C. J., Shen, L., Wittenberg, G. M., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.06.012 · Cited by 176
Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173
Evans, J. W., Szczepanik, J., Brutsché, N., Park, L. T., Nugent, A. C., & Zarate, C. A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.027 · Cited by 173
Self-citationEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Self-citationNichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · cited 1×
“, 1997), and both LSD and DOI administration in rodent models increased expression of Bdnf, Arc, Nor1, egr-1, sgk, Ania3, C/EBP-β, and Iκβ-α (Nichols and Sanders-Bush, 2002; Nichols et al., 2003; González-Maeso et al., 2007; Martin et al., 2014; Martin and Nichols, 2016).”
BackgroundChen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.078 · Cited by 159
Branchi, I. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.08.011 · Cited by 156
Cavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationPsychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · cited 1×
“In particular, growing evidence suggests that particular experiences during the psychoactive period are uniquely predictive of therapeutic outcome with SPs (Kyzar et al., 2017).”
BackgroundScruggs, J. L., Schmidt, D. E., & Deutch, A. Y. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00547-0 · Cited by 138
Razoux, F., Garcia, R., & Léna, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301057 · Cited by 135
Muschamp, J. W., Regina, M. J., Hull, E. M., Winter, J. C., & Rabin, R. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.044 · Cited by 129
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128
Höflich, A., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Windischberger, C., Saria, A., Kasper, S., Winkler, D., & Lanzenberger, R. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv040 · Cited by 125
de la Salle, S., Choueiry, J., Shah, D., Bowers, H., McIntosh, J., Ilivitsky, V., & Knott, V. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00348 · Cited by 118
Behavioral Neurobiology of Psychedelic Drugs
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-662-55880-5 · Cited by 118
Subanaesthetic ketamine and altered states of consciousness in humans
Vlisides, P. E., Bel-Bahar, T., Nelson, A., Chilton, K., Smith, E., Janke, E., Tarnal, V., Picton, P., Harris, R. E., & Mashour, G. A. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.03.011 · Cited by 114
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
Self-citationAcute biphasic effects of ayahuasca.
Schenberg, E. E., Alexandre, J. F. M., Filev, R., Cravo, A. M., Sato, J. R., Muthukumaraswamy, S. D., Yonamine, M., Waguespack, M., Lomnicka, I., Barker, S. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137202 · Cited by 111
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110
Self-citationGregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 103
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Cortical dynamics during psychedelic and anesthetized states induced by ketamine
Li, D., & Mashour, G. A. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.03.076 · Cited by 92
Fukumoto, K., Iijima, M., Funakoshi, T., & Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx116 · Cited by 90
Martin, D. A., & Nichols, C. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.049 · Cited by 86
Lima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
Nichols, C. D., Garcia, E. E., & Sanders-Bush, E. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00029-9 · Cited by 82
Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
van Schalkwyk, G. I., Wilkinson, S. T., Davidson, L., Silverman, W. K., & Sanacora, G. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.023 · Cited by 76
Lambe, E. K., & Aghajanian, G. K. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300944 · Cited by 75 · cited 2×
“Studies similarly suggest that SPs cause a glutamate surge, primarily in layer V pyramidal neurons expressing 5-HT2A receptors (Lambe and Aghajanian, 2006; De Gregorio et al., 2018).”
BackgroundRéus, G. Z., Nacif, M. P., Abelaira, H. M., Tomaz, D. B., dos Santos, M. A. B., Carlessi, A. S., da Luz, J. R., Gonçalves, R. C., Vuolo, F. S., Dal‐Pizzol, F., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.022 · Cited by 75
Marek, G. J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_480 · Cited by 75
Müller, F., Musso, F., London, M. K., de Boer, P., Zacharias, N., & Winterer, G. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.05.037 · Cited by 75
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
Self-citationZacharias, N., Musso, F., Müller, F., Lammers‐Lietz, F., Saleh, A., London, M. K., de Boer, P., & Winterer, G. (2019) · Human Brain Mapping · doi:10.1002/hbm.24791 · Cited by 74
Treccani, G., Ardalan, M., Chen, F., Musazzi, L., Popoli, M., Wegener, G., Nyengaard, J. R., & Müller, H. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1613-3 · Cited by 73 · cited 1×
“In addition, in the Flinders Sensitive Line rat model of depression, ketamine rapidly restored apical dendritic spine deficits in pyramidal neurons of the hippocampal CA1 region within 60 minutes of infusion (Treccani et al., 2019).”
BackgroundGilbert, J. R., & Zarate, C. A. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172856 · Cited by 73
Self-citationde Bartolomeis, A., Sarappa, C., Buonaguro, E. F., Marmo, F., Eramo, A., Tomasetti, C., & Iasevoli, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.010 · Cited by 72
Abdallah, C. G., Dutta, A., Averill, C. L., McKie, S., Akiki, T. J., Averill, L. A., & William Deakin, J. F. (2018) · Chronic Stress · doi:10.1177/2470547018796102 · Cited by 70
Nugent, A. C., Wills, K. E., Gilbert, J. R., & Zarate, C. A. (2019) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2018.09.001 · Cited by 69
Self-citationChronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia
Martin, D. A., Marona-Lewicka, D., Nichols, D. E., & Nichols, C. D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.013 · Cited by 67
Ketamine normalizes brain activity during emotionally valenced attentional processing in depression
Reed, J. L., Nugent, A. C., Furey, M. L., Szczepanik, J. E., Evans, J. W., & Zarate, C. A. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.07.006 · Cited by 67
Self-citationAust, S., Gärtner, M., Basso, L., Otte, C., Wingenfeld, K., Chae, W. R., Heuser-Collier, I., Regen, F., Cosma, N. C., van Hall, F., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.005 · Cited by 67
Zhang, C., & Marek, G. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.009 · Cited by 65
Modulation of amygdala reactivity following rapidly acting interventions for major depression
Loureiro, J. R. A., Leaver, A., Vasavada, M., Sahib, A. K., Kubicki, A., Joshi, S., Woods, R. P., Wade, B., Congdon, E., Espinoza, R., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24895 · Cited by 64
Atasoy, S., Vohryzek, J., Deco, G., Carhart-Harris, R. L., & Kringelbach, M. L. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.009 · Cited by 63
The Effects of Hallucinogens on Gene Expression
Martin, D. A., & Nichols, C. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_479 · Cited by 61
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C. H., Li, X., Chaki, S., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0705-0 · Cited by 59
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives
Pallavicini, C., Vilas, M. G., Villarreal, M., Zamberlan, F., Muthukumaraswamy, S., Nutt, D., Carhart-Harris, R., & Tagliazucchi, E. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.06.053 · Cited by 58
Kolp, E., Friedman, H. L., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., Hospital, A., Sylvester, M., Young, M. S., University of South Florida, et al. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.84 · Cited by 54
Kraus, C., Mkrtchian, A., Kadriu, B., Nugent, A. C., Zarate, C. A., & Evans, J. W. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0624-0 · Cited by 54
Self-citationHeal, D. J., Gosden, J., & Smith, S. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.049 · Cited by 49
Fleming, L. M., Javitt, D. C., Carter, C. S., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101739 · Cited by 37
Lascelles, K. M., Marzano, L., Brand, F., Trueman, H., McShane, R. H., & Hawton, K. E. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029108 · Cited by 36
Drewniany, E., Han, J., Hancock, C., Jones, R. L., Lim, J., Gorgani, N. N., Sperry, J., Yu, H. J., & Raffa, R. B. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12238 · Cited by 34
Some Comments on Psychedelic Research
Schatzberg, A. F. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030272 · Cited by 21
Pereira, V. S., Elfving, B., Joca, S. R. L., & Wegener, G. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.029 · Cited by 16
Research works printed but not linked: 1
- McKenna, 2018, New world tryptamine hallucinogens and the neuroscience of ayahuasca., 283
Cited by
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
“This has been hypothesized to be modulated by increases in BDNF/TrkB signaling [192].”
BackgroundKundakovic, M., & Rocks, D. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101010 · Cited by 317
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Self-citation
Metadata
- Authors
- Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Kadriu, Bashkim
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-30
- Volume
- 24
- Issue
- 1
- Pages
- 8-21
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816692
- OpenAlex
- W3108229983
- Cited by
- 99
- References
- 145
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 22 · 2023: 15 · 2022: 23 · 2021: 12 · 2020: 1
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health
- National Institutes of Health (ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, serotonergic psychedelics, rapid-acting antidepressants, antidepressant mechanism, glutamatergic signaling, cortical network activity, psychoactive effects, network efficiency
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Hallucinogens, Humans, Ketamine, Serotonin Agents, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.